{
    "clinical_study": {
        "@rank": "132945", 
        "arm_group": [
            {
                "arm_group_label": "Atacicept 75 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Atacicept 150 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II\n      core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of\n      atacicept in subjects with systemic lupus erythematosus (SLE). The Week 24 visit of ADDRESS\n      II core trial will coincide with the Day 1 visit of this LTE trial."
        }, 
        "brief_title": "Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Erythematosus, Systemic", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have completed the 24-week treatment period of trial EMR-700461-023\n             (ADDRESS II core trial)\n\n          -  Women of childbearing potential who have a negative pregnancy test\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Active neurological symptoms of SLE that are deemed severe or progressive\n\n          -  Diagnosis of any demyelinating disease, such as, but not restricted to, multiple\n             sclerosis (MS) or optic neuritis\n\n          -  Pregnancy\n\n          -  Active clinically significant viral, bacterial, or fungal infection, or any major\n             episode of infection that in the investigator's opinion makes the subject unsuitable\n             to continue participation in the trial\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "213", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070978", 
            "org_study_id": "700461-024", 
            "secondary_id": "2013-002758-62"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atacicept 75 mg", 
                "description": "Subjects who received 75 mg atacicept in the ADDRESS II trial, will continue receiving 75 mg atacicept as subcutaneous injection once weekly for 96 weeks in this trial.", 
                "intervention_name": "Atacicept 75 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atacicept 150 mg", 
                "description": "Subjects who received placebo or 150 mg atacicept in the ADDRESS II trial, will receive 150 mg atacicept as subcutaneous injection once weekly for 96 weeks in this trial.", 
                "intervention_name": "Atacicept 150 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lupus Erythematosus, Systemic", 
            "Atacicept 75 and 150 mg", 
            "LTE"
        ], 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "for US recruiting sites", 
                    "phone": "888-275-7376"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockland", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Please Contact US Medical Information"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "service@merckgroup.com", 
                    "last_name": "for EU recruiting sites", 
                    "phone": "+49 6151 72 5200"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }, 
                    "name": "Please contact the Merck KGaA Communication Center"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_contact_backup": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Subjects With at least one Serious Adverse Event (SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 weeks"
            }, 
            {
                "measure": "Number of Subjects Prematurely Discontinuing the treatment due to Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070978"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Organ Damage Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Disease Activity as Measured by British Isles Lupus Assessment Group (BILAG) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Disease Activity as Measured by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Disease Activity as Measured by SLEDAI-2K Responder Index-50 (SRI-50) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Disease Activity as Measured by Physician's Global Assessment (PGA) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in SLE Responder Index (SRI) (a Disease Activity Composite Index)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in BILAG-based Combined Lupus Assessment (BICLA) (a Disease Activity Composite Index)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Prednisone-equivalent Corticosteroid Dose", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Lupus Quality of Life Questionnaire (LupusQoL) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Patient Global Impression of Change (PGIC) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in EuroQoL 5 Dimension Instrument (EQ-5D) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 96"
            }, 
            {
                "measure": "Number of Subjects with at least one AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 weeks"
            }, 
            {
                "measure": "Columbia-Suicide Severity Rating Scale (C-SSRS) Score", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 weeks"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}